Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Deanna Ballard

Nurse Practitioner, Primary Care Danbury, CT Nurse Practitioner

NPI 1659733657 CMS profile 11157309

95 Locust Ave, Danbury, CT 06810

Open in the dashboard

General payments

$7,331

302 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Deanna Ballard of Danbury, CT is reported in the CMS Open Payments database as having received $7,331 across 302 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,726 72
2024 General $2,609 115
2023 General $1,892 84
2022 General $1,075 30
2021 General $30 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Deanna Ballard
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Deanna Ballard were reported at $1,726. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Deanna Ballard Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $30 $137 $39–$445 $132
2022 $1,075 $139 $44–$421 $149
2023 $1,892 $163 $53–$481 $160
2024 $2,609 $176 $54–$511 $164
2025 $1,726 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Celgene Corporation $592 43 payments
  2. Janssen Biotech, Inc. $576 22 payments
  3. AbbVie, Inc. $567 24 payments
  4. Novartis Pharmaceuticals Corporation $565 27 payments
  5. Seattle Genetics, Inc. $540 11 payments
  6. Incyte Corporation $453 11 payments
  7. AstraZeneca Pharmaceuticals LP $382 15 payments
  8. Aveo Pharmaceuticals, Inc. $334 6 payments
  9. Pfizer Inc. $313 14 payments
  10. E.R. Squibb & Sons, L.L.C. $280 11 payments
  11. Other $2,729 118 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,890 286 payments
  2. Education $1,442 16 payments
Products named General payments · program years 2021–2025
  1. IMBRUVICA $561 23 payments
  2. EPKINLY $462 20 payments
  3. FOTIVDA $334 6 payments
  4. KISQALI $331 18 payments
  5. REBLOZYL $268 15 payments
  6. TECVAYLI $194 5 payments
  7. OPDIVO $192 10 payments
  8. LIBTAYO $187 9 payments
  9. RYBREVANT $186 5 payments
  10. DARZALEX $185 4 payments
  11. Other $4,750 232 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$4,239

Medicare's payments for the services billed

Medicare patients

47

Average age 75

Services billed

90

22 women, 25 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Cancer 57%
Arthritis 43%
Ischemic heart disease 38%
Chronic kidney disease 30%
Diabetes 28%
Atrial fibrillation 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 62 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EPKINLY
  • AbbVie, Inc. $187
$187 — —
IMBRUVICA
  • AbbVie, Inc. $132
$132 — —
ENHERTU
  • Daiichi Sankyo Inc. $72
  • AstraZeneca Pharmaceuticals LP $49
$121 — —
FOTIVDA
  • Aveo Pharmaceuticals, Inc. $120
$120 — —
KISQALI
  • Novartis Pharmaceuticals Corporation $117
$117 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 62 with Patron

Records

302 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record